s/gsk1349572

Dolutegravir sodium (GSK-1349572A) salt(DTG; GSK1349572) is an HIV integrase inhibitor(IC50: 2.7 nM), modest activity against raltegravir-resistant signature mutants Y143R, Q148K, N155H, and G140S/Q148H.

Dolutegravir (GSK1349572) (IC50=2.7 nM), a two-metal-binding HIV integrase inhibitor, exhibits medium activity against raltegravir-resistant signature mutants Y143R, Q148K, N155H, and G140S/Q148H.

Dolutegravir-d5 is the deuterated form of Dolutegravir. Dolutegravir (S/GSK1349572) is a potent, orally administered HIV integrase strand transfer inhibitor, with an IC50 of 2.7 nM in the chain-transfer catalyzed by HIV-1 integrase. It effectively inhibits the replication of HIV-1 in peripheral blood mononuclear cells with an IC50 of 0.51 nM. Additionally, Dolutegravir (S/GSK1349572) remains effective against Y143R, N155H, and G140S/Q148H mutants, with an EC50 ranging from 3.6 to 5.8 nM.

Dolutegravir-d3 is a deuterated form of Dolutegravir. Dolutegravir (S/GSK1349572) acts as a potent, orally administered inhibitor of HIV integrase strand transfer, showing an IC50 value of 2.7 nM during the catalysis of strand transfer by HIV-1 integrase. Additionally, Dolutegravir (S/GSK1349572) effectively inhibits the replication of HIV-1 virus in peripheral blood mononuclear cells, with an IC50 of 0.51 nM.